modern medicamentous treatment of epilepsy in adults
Article Quality & Performance Metrics
Readership in this journal
SteadyRanked #207 of 231 articles by views in planta medica
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 231 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
Background: Several »newer« antiepileptic drugs (AEDs), i.e. vigabatrin, lamotrigine, gabapentin, topiramate, tiagabine, oxcarbazepine, levetiracetam, pregabalin and zonisamide have been introduced into clinical practice within the last decade. Most of these new drugs are at least as effective as the »older« AEDs (phenobarbital, phenytoin, valproic acid, carbamazepine) and in general, they seem to be better tolerated then the older drugs and have less side effects. The development of pharmaceutical industry has brought several new AEDs to clinical practice which increased a probability of therapeutic success, but also made treatment more complex. It is expected from the physician that she will know indications and contraindications for at least 15 AEDs, their optimal titration, dosage, possible side effects and wide spectrum of interactions with other drugs. At this point advertisements of drug companies try to convince us aggressively about success of their own products.
Conclusions: This review article focuses on modern medicamentous treatment of adults with epilepsy, main characteristics of newer AEDs, conditions, availability and statistics of their usage in Slovenia.
| Reference Key |
zgonc2006zdravnikimodern
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Vid Zgonc;Boštjan Čebular |
| Journal | planta medica |
| Year | 2006 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.